Category: Zacks Small Cap Research

16061626364620 / 632 POSTS
By Brian Marckx, CFA  NASDAQ:CTSO Q3 Financials / Operating Update: Germany Reimbursement Rebounds, Drives Strong Record Product Sales…  CytoSorbents (NASDAQ:CTSO) reported financial results for their third quarter ending September 30th an ...
By Anita Dushyanth, PhD NASDAQ:VRAY Financial UpdateOn November 13, 2017 VRAY (NASDAQ:VRAY) announced third quarter financial results.The firm recorded revenue of little over $12 million for the quarter.  Management had originally guided for tot ...
By David Bautz, PhD NASDAQ:SPHS Financial UpdateOn November 9, 2017, Sophiris Bio, Inc. (NASDAQ:SPHS) announced financial results for the third quarter of 2017. As expected, the company did not report any revenues during the quarter. The company rep ...
By Brian Marckx, CFA NASDAQ:CASM Q3 Financial ResultsCAS Medical (NASDAQ:CASM) reported financial results for the third quarter ending September 30th.  Revenue was very much inline with our number and a relatively healthy beat on both gross marg ...
By Brian Marckx, CFA NASDAQ:CEMI Q3 2017: Upside from Lateral Flow OTC. DPP HIV/Syph, Several DPP Fever Products to Drive 2018 Growth …Chembio (NASDAQ:CEMI) reported Q3 2017 financial results and provided a business update.  Relative to our esti ...
By Ian Gilson, PhD, CFA NASDAQ:ESDI During a conference call Eastside Distilling (NASDAQ:ESDI) management and John Rich outlined the opportunities for the joint venture of Eastside and Rich Marks. Rich Marks is an established name in the U.S.A. ...
By Lisa Thompson NASDAQ:NETE Results for Q3 2017 were negatively affected by both the restructuring of Net Element’s (NASDAQ:NETE) Russian operations and the recent hurricanes. In Q4 however, operations, growth, and margins should be back to normal. ...
By John Vandermosten, CFA OTC:ONCYF TSX:ONC.TO Oncolytics Biotech (OTC:ONCYF) (TSX:ONC.TO) announced a licensing deal with Adlai Nortye (NEEQ: 870946) to provide upfront licensing and milestones of $21.2 million to support the Phase III effort for RE ...
By David Bautz, PhDNYSE:APHBBusiness UpdateAdditional Patients Treated Under Expanded Access ProtocolAmpliPhi Biosciences Corp. (NYSE:APHB) is developing bacteriophage therapeutics for the treatment of bacterial infections. AmpliPhi’s ...
By David Bautz, PhDNASDAQ:AGRXAgile Therapeutics, Inc. (NASDAQ:AGRX) is a women’s healthcare company focused on developing healthcare products to fulfill the unmet contraceptive needs of women. The company’s lead candidate product, Twirla® (AG200-15 ...
16061626364620 / 632 POSTS